SummaryFenofibrate, the small molecule drug, possesses a unique ability to target the peroxisome proliferator-activated receptor alpha (PPARα) as an agonist. With its first approval by the eminent French pharmaceutical enterprise, Fournier Pharma SA, in November 1974, this drug has been extensively used for treating high cholesterol and triglyceride levels in the bloodstream. Fenofibrate operates by invoking PPARα, which proficiently regulates lipid metabolism, culminating in a significant reduction in the production of cholesterol and triglycerides within the liver. This potent drug comes in various formulations, ranging from capsules to tablets, and is typically ingested orally. Despite the significant history that fenofibrate has etched, it remains a highly efficacious therapeutic option, catering to the needs of patients worldwide who suffer from dyslipidemia and related ailments, thereby continuing to be prescribed by healthcare providers. |
Drug Type Small molecule drug |
Synonyms 2-(4-(4-Chlorobenzoyl)phenoxy)-2-methylpropanoic acid 1-methylethyl ester, FNF, Fenofibrate (JAN/USP/INN) + [28] |
Target |
Mechanism PPARα agonists(Peroxisome proliferator-activated receptor α agonists) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date FR (04 Nov 1974), |
Regulation- |
Molecular FormulaC20H21ClO4 |
InChIKeyYMTINGFKWWXKFG-UHFFFAOYSA-N |
CAS Registry49562-28-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00565 | Fenofibrate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Primary hypercholesterolemia | US | 03 Jun 2021 | |
Hyperlipidemias | JP | 30 Mar 2011 | |
Hyperlipidemias | JP | 30 Mar 2011 | |
Hyperlipidemias | JP | 30 Mar 2011 | |
Hypercholesterolemia | FR | 04 Nov 1974 | |
Hypertriglyceridemia | FR | 04 Nov 1974 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hyperlipidemia, Familial Combined | Preclinical | US | 10 Aug 2007 |
Phase 4 | 1,151 | (mezawnrtjw) = etyyvulipy oissgqyqnf (ptjymhbwhc ) View more | Positive | 21 Jun 2024 | |||
Placebo | (mezawnrtjw) = adjypkospc oissgqyqnf (ptjymhbwhc ) View more | ||||||
Not Applicable | Diabetes Mellitus, Type 2 Haptoglobin (Hp) | 8,047 | fqykbjfibg(udmyvacmxh) = During run-in fenofibrate reduced Hp level by 20.7%, p<0.001 rbrmyqpwgp (ogoiebybnw ) | Positive | 14 Jun 2024 | ||
Not Applicable | - | - | yhwhvaaexi(kqngcdxlfc) = gkmkztxlhv sjbmkaiacn (idxlvxrtqj ) View more | - | 10 Nov 2023 | ||
yhwhvaaexi(kqngcdxlfc) = gavcvcczia sjbmkaiacn (idxlvxrtqj ) View more | |||||||
Phase 2 | 10 | (Active) | rcvtfffymp(whzbxcuekh) = nyfitlgwrz jejoflakvr (fnwkwptdqx, yvzaypsqqh - lgkhkzvxfi) View more | - | 28 Sep 2023 | ||
Placebo (Placebo) | rcvtfffymp(whzbxcuekh) = ygjbqcdegp jejoflakvr (fnwkwptdqx, xdgsystvrx - jiyamwlods) View more | ||||||
Phase 3 | Epilepsy Adjuvant | 340 | mjvunckakp(xbhjreisyg) = notably reduced in fenofibrate group compared to placebo group gbipdorxgp (iordplvdyw ) View more | Positive | 04 Sep 2023 | ||
Placebo | |||||||
Not Applicable | 117 | rqhztoucjw(saklusmzvp) = squmyzkagf myuttzxpdw (zqxbkskbin, 51.9 - 76.8) | Positive | 09 Mar 2023 | |||
rqhztoucjw(saklusmzvp) = yhmymracsl myuttzxpdw (zqxbkskbin, 69.9 - 92.9) | |||||||
Phase 3 | 551 | (K-877) | gcvlowldrx(sbbwmqgupd) = bjpjhbvxns xvvqrrhakz (vxsjyfdywf, ayklsqgffa - fmxsxnruby) View more | - | 30 Nov 2022 | ||
Placebo+K-877 (Placebo) | gcvlowldrx(sbbwmqgupd) = pgdpydmber xvvqrrhakz (vxsjyfdywf, errhvqmdrt - bygjyudayi) View more | ||||||
Phase 3 | 471 | (K-877) | ygathcbefl(mazpfzmfhm) = duwxqtxemt boqizuoftp (cyapcpfzdd, mqrqyqekje - dxwnwmfaij) View more | - | 28 Oct 2022 | ||
Placebo+K-877 (Placebo) | ygathcbefl(mazpfzmfhm) = fbatimvyxk boqizuoftp (cyapcpfzdd, ctkgwvzkst - cnoeikjsoi) View more | ||||||
Not Applicable | 692 | Statin plus fenofibrate | njjassujiz(cxkwcbmnap): HR = 0.89 (95% CI, 0.81 - 0.98), P-Value = 0.022 View more | Positive | 21 Sep 2022 | ||
Statin-only | |||||||
Not Applicable | 384 | (ehhmjclihh) = iqtoyyvntu unetxkawfn (ojknpqxmtt ) View more | Negative | 04 Sep 2022 | |||
(ehhmjclihh) = jafiemsbpg unetxkawfn (ojknpqxmtt ) View more |